LSITIRPR* – SIL Dupilumab signature peptide quantifier


LSITIRPR Stable Isotope Labeled Infliximab (DPL) peptide serves as an internal standard to confirm DPL’s primary sequence by mass spectrometry. This allows expected sequences to be confirmed and terminal amino acid homogeneity to be assessed.

SB-PEPTIDE’s Dupilumab SIL signature peptide quantifier is designed and optimized to provide the best mass spectrometry performance during your Mass Spec assay. For a better detection and quantification, you can use Dupilumab SIL peptide qualifier, that will induce a complementary signal, with a lower signal-to-noise ratio, for DPL presence confirmation.

Technical specification

APYTFGQGTK - SIL buy Sequence : LSITIRP-R*-  [R*= R(13C/15N)]
APYTFGQGTK - SIL synthesis MW : 965.08 Da (C42H78N14O11)
APYTFGQGTK - SIL standard price Purity : > 95%
APYTFGQGTK - SIL peptide standard synthesis Counter-Ion : TFA Salts (see option TFA removal)
Peptide library synthesis abeta peptide Delivery format : Freeze dried in propylene 2mL microtubes
buy synthesized peptide standard Other name : SIL DPL signature peptide quantifier
APYTFGQGTK - SIL standard solubility guidelines Peptide Solubility Guideline
buy peptide price Bulk peptide quantities available


Catalog code Size Price € Price $ USD
SB294-0.1MG 0.1 mg 350 437,5